In this webinar, you will learn:
- How integrated protein sequencing, SPR, and HDX-MS workflows can accelerate anti-idiotype antibody discovery pipelines.
- Strategies to discover all three functional anti-idiotype antibody subtypes with strong functional performance and low cross-reactivity to endogenous human IgG.
- How advanced characterization techniques can reveal affinity, specificity, subtype classification, and epitope-level binding differences between anti-idiotype candidates.
- How newly discovered anti-idiotype antibodies compared against commercially available reagents across key performance metrics.
Anti-Idiotype Antibody Discovery
Biotherapeutics represent one of the fastest-growing areas in modern medicine, with the global market projected to exceed $1 trillion by 2030. Anti-idiotype antibodies are essential tools for studying and monitoring biotherapeutics through ADME studies and clinical trials. Different anti-idiotype subtypes serve distinct analytical purposes, making highly specific and well-characterized anti-idiotype antibodies critical for pharmacokinetic, pharmacodynamic, and immunogenicity assays.
Despite their importance, anti-idiotype antibody discovery remains challenging due to the requirements for high affinity, high specificity, and the need for fast results to support development of the therapeutic molecule.
In this webinar, we present a comprehensive study exploring how protein-first antibody discovery, SPR, and HDX-MS can be combined into a streamlined anti-idiotype discovery workflow. Using adalimumab as a model system, we evaluated newly discovered recombinant anti-idiotype antibodies alongside commercially available reagents to investigate how our candidates compare across affinity, specificity, binding kinetics, epitope diversity, and functional subtype behavior.
Join us to see how advanced characterization approaches are uncovering functional and structural insights beyond conventional screening methods.
Speaker Bios
Thierry Le Bihan
Rapid Novor
Thierry obtained his PhD from Université Laval and was previously an associate professor at the University of Edinburgh before joining Rapid Novor. With his extensive experience in proteomics, Thierry leads the polyclonal antibody sequencing efforts and built the platform from the ground up. He dedicates his time to researching innovative ways to explore the immune system through next-generation protein sequencing.
Taylor Clarke
Sales Development Representative
Rapid Novor